IRON
Disc Medicine, Inc.
NasdaqGM Healthcare United States
63,33 $US
-1.83% today
-19.93% YTD · -8.59% 1Y
32
Insider transactions
SEC Form 4 · AMF · BaFin — rolling 90 days
17
Hedge funds tracked
Latest available SEC 13F filings
50
/ 100
MIXED

Analysis Disc Medicine, Inc. (IRON) — Kairos Score 50/100

Composite score aggregating 8 smart money dimensions: insiders (SEC/AMF/BaFin), hedge funds, politicians & gurus, price momentum, valuation, analyst consensus, financial health, earnings momentum. The higher the score, the more favorable the institutional signals consensus.

💡 Detailed breakdown (the 8 sub-scores) available in the Premium dashboard.

About Disc Medicine, Inc.

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. The company was founded in 2017 and is headquartered in Watertown, Massachusetts.

Key info

👔
CEO
Dr. John D. Quisel Esq., J.D., Ph.D.
📍
HQ
321 Arsenal Street, Suite 101, Watertown, MA, 02472, United States
👥
Employees
165
💰
Market cap
2 436 026 100,00 $US
💸
Dividend yield
—

🕴️ Insider activity (90 days)

32 transactions — 0 buys and 23 sales reported by Disc Medicine, Inc. executives.

QJ
Quisel John D
Chief Executive Officer · 2026-09-15
Other
BK
Bitterman Kevin
2026-09-11
Other
BK
Bitterman Kevin
2026-09-11
Other

🏦 Hedge Funds

17 institutional funds report a position on IRON in their latest SEC quarterly filing.

FMR LLC
BlackRock, Inc.
RA CAPITAL MANAGEMENT, L.P.
VANGUARD GROUP INC
JPMORGAN CHASE & CO

📰 Recent news

15 recent articles on IRON.

🧠 What makes Kairos Insider

Beyond raw data, we aggregate and score every smart money signal to give you a unique view.

🧠

Kairos Score 0-100

8-dimension composite score: insiders · hedge funds · politicians · momentum · valuation · health · analysts · earnings.

🎯

Insider Clusters

Detection of clustered purchases or sales by several executives in the same stock.

🏦

13F Hedge Funds

Berkshire, Pershing Square, Tiger Global, Bridgewater and other reporting funds.

📈

ETF Rotations

NANC & GOP (Pelosi & Republicans), GURU (top hedge funds), ARK (Cathie Wood). See who enters and exits each week.

🔥

Google Trends

Spot marked changes in search interest around the stocks being followed.

📧

Email alerts

Create your watchlist and receive a brief of events affecting your tickers.

Companies in the same sector as Disc Medicine, Inc.

Official sources · Public data · SEC EDGAR — Form 4 & 13F · AMF — Executive filings · BaFin — Directors' Dealings · Yahoo Finance · Alpha Vantage

🔓 Unlock the full analysis

This public page only shows a preview. The full analysis of IRON on the Kairos Insider dashboard includes:

✅ Full Kairos Score (8-axis radar + synthesis)
✅ History of all 32 insider transactions over 90 days
✅ All 17 detected institutional funds
✅ Thematic ETFs (ARK, BUZZ, NANC, GOP, JEPI…)
✅ Hot Stocks Google Trends
✅ Available history: AUM + rotations
✅ Fundamentals (P/E, PEG, EV/EBITDA, ROE…)
✅ Financial health (Altman Z, Piotroski F)
✅ Sector peers + recent earnings
See full analysis →
Analyze other tickers for free →

Free signup · Pro €19/month or €190/year